{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:44:55Z","timestamp":1789706695502,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2012\/12957-5"],"award-info":[{"award-number":["2012\/12957-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["141564\/2012-1"],"award-info":[{"award-number":["141564\/2012-1"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["141542\/2012-8"],"award-info":[{"award-number":["141542\/2012-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["311543\/2014-6"],"award-info":[{"award-number":["311543\/2014-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.bcmd.2015.07.005","type":"journal-article","created":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T00:14:25Z","timestamp":1436487265000},"page":"236-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["CALR mutations screening in wild type JAK2V617F and MPLW515K\/L Brazilian myeloproliferative neoplasm patients"],"prefix":"10.1016","volume":"55","author":[{"given":"Daniela Prudente Teixeira","family":"Nunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciene Terezina","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de Lourdes","family":"Chauffaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mitne-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Tadeu","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Gil","family":"Cliquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira Maria","family":"Guerra-Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2015.07.005_bb0005","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMe1313643","article-title":"Another piece of the myeloproliferative neoplasms puzzle","volume":"369","author":"Levine","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0010","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0035","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0040","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0045","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0055","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0060","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0065","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0070","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0075","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0080","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0085","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0090","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0095","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-014-2232-8","article-title":"Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring","volume":"94","author":"Chi","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3343\/alm.2015.35.1.22","article-title":"Calreticulin exon 9 mutations in myeloproliferative neoplasms","volume":"35","author":"Ha","year":"2015","journal-title":"Ann. Lab. Med."},{"issue":"3","key":"10.1016\/j.bcmd.2015.07.005_bb0110","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s12253-014-9885-4","article-title":"JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis","volume":"21","author":"P\u00f3sfai","year":"2015","journal-title":"Pathol. Oncol. Res."},{"issue":"5","key":"10.1016\/j.bcmd.2015.07.005_bb0115","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2014.343","article-title":"CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis","volume":"29","author":"Finazzi","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0120","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3324\/haematol.2014.115113","article-title":"JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms","volume":"100","author":"Shirane","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0125","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Bros\u00e9us","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0130","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2014.49","article-title":"Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"28","author":"Bros\u00e9us","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0135","first-page":"1","article-title":"Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis","author":"Zamora","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0140","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0145","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjh.12969","article-title":"JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort","volume":"167","author":"McGaffin","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.bcmd.2015.07.005_bb0150","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00277-014-2248-0","article-title":"A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients","volume":"94","author":"Xu","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0155","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0160","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0165","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/jclinpath-2013-201822","article-title":"Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K\/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms","volume":"67","author":"dos Santos","year":"2014","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/17474086.2014.920250","article-title":"Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms","volume":"7","author":"Guglielmelli","year":"2014","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0175","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrclinonc.2014.16","article-title":"Genetics: CALR mutations and a new diagnostic algorithm for MPN","volume":"11","author":"Tefferi","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0180","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0185","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Andrikovics","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0190","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/367476a0","article-title":"Modulation of gene expression by calreticulin binding to the glucocorticoid receptor","volume":"367","author":"Burns","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0195","doi-asserted-by":"crossref","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.bcmd.2015.07.005_bb0200","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/gtmb.2014.0184","article-title":"Considerations and recommendations for a new molecular diagnostic algorithm for the myeloproliferative neoplasms","volume":"18","author":"Haslam","year":"2014","journal-title":"Genet. Test Mol. Biomark."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0205","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2014.109199","article-title":"Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients","volume":"99","author":"Qiao","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0210","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-014-0048-6","article-title":"The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"7","author":"Wu","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1073\/pnas.0126614100","article-title":"Color and genomic ancestry in Brazilians","volume":"100","author":"Parra","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0220","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1590\/S0100-879X2009005000026","article-title":"DNA tests probe the genomic ancestry of Brazilians","volume":"42","author":"Pena","year":"2009","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0225","doi-asserted-by":"crossref","first-page":"e17063","DOI":"10.1371\/journal.pone.0017063","article-title":"The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected","volume":"6","author":"Pena","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2015.07.005_bb0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ejhg.2011.144","article-title":"Brazilian urban population genetic structure reveals a high degree of admixture","volume":"20","author":"Giolo","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.bcmd.2015.07.005_bb0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ejh.12389","article-title":"Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history","volume":"94","author":"Gangat","year":"2015","journal-title":"Eur. J. Haematol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:31:36Z","timestamp":1761049896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979615001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1079979615001333"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.07.005","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CALR mutations screening in wild type JAK2V617F and MPLW515K\/L Brazilian myeloproliferative neoplasm patients","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}